JP2021517813A5 - - Google Patents
Info
- Publication number
- JP2021517813A5 JP2021517813A5 JP2020548778A JP2020548778A JP2021517813A5 JP 2021517813 A5 JP2021517813 A5 JP 2021517813A5 JP 2020548778 A JP2020548778 A JP 2020548778A JP 2020548778 A JP2020548778 A JP 2020548778A JP 2021517813 A5 JP2021517813 A5 JP 2021517813A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- modified
- antigen
- adjuvant
- input
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024188260A JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862641987P | 2018-03-12 | 2018-03-12 | |
| US62/641,987 | 2018-03-12 | ||
| US201862738941P | 2018-09-28 | 2018-09-28 | |
| US62/738,941 | 2018-09-28 | ||
| US201962794516P | 2019-01-18 | 2019-01-18 | |
| US62/794,516 | 2019-01-18 | ||
| PCT/US2019/021705 WO2019178006A2 (en) | 2018-03-12 | 2019-03-11 | Intracellular delivery of biomolecules to modify immune response |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Division JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517813A JP2021517813A (ja) | 2021-07-29 |
| JPWO2019178006A5 JPWO2019178006A5 (https=) | 2022-03-18 |
| JP2021517813A5 true JP2021517813A5 (https=) | 2022-03-18 |
| JP7595827B2 JP7595827B2 (ja) | 2024-12-09 |
Family
ID=66102189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548778A Active JP7595827B2 (ja) | 2018-03-12 | 2019-03-11 | 免疫応答を改変するための生体分子の細胞内送達 |
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024188260A Pending JP2025020210A (ja) | 2018-03-12 | 2024-10-25 | 免疫応答を改変するための生体分子の細胞内送達 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240374654A2 (https=) |
| EP (1) | EP3765068A2 (https=) |
| JP (2) | JP7595827B2 (https=) |
| KR (1) | KR20200130835A (https=) |
| CN (1) | CN112135627A (https=) |
| AU (2) | AU2019234550B2 (https=) |
| BR (1) | BR112020018612A2 (https=) |
| CA (1) | CA3093828A1 (https=) |
| CO (1) | CO2020012584A2 (https=) |
| CR (1) | CR20200460A (https=) |
| IL (1) | IL277188B2 (https=) |
| MA (1) | MA52010A (https=) |
| MX (1) | MX2020009439A (https=) |
| PH (1) | PH12020551436A1 (https=) |
| SG (1) | SG11202008864VA (https=) |
| TW (1) | TW202003019A (https=) |
| WO (1) | WO2019178006A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
| JP7602702B2 (ja) | 2016-05-03 | 2024-12-19 | ステムセル テクノロジーズ カナダ インコーポレーテッド | 寛容性を誘導するための生体分子の細胞内送達 |
| US12599656B2 (en) | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
| WO2020014543A2 (en) | 2018-07-11 | 2020-01-16 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP6884450B2 (ja) * | 2019-02-14 | 2021-06-09 | 学校法人獨協学園獨協医科大学 | Ｔ細胞ワクチン |
| CA3131701A1 (en) | 2019-02-28 | 2020-09-03 | Sqz Biotechnologies Company | Delivery of biomolecules to pbmcs to modify an immune response |
| US11679388B2 (en) | 2019-04-08 | 2023-06-20 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
| AU2021272340A1 (en) | 2020-05-11 | 2022-12-08 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
| EP4188425B1 (en) | 2020-07-29 | 2025-05-14 | Stemcell Technologies Canada Inc. | Methods to stimulate immune responses to mutant ras using anucleate cells |
| WO2022026620A1 (en) | 2020-07-29 | 2022-02-03 | Sqz Biotechnologies Company | Methods to stimulate immune responses to mutant ras using nucleated cells |
| TW202241466A (zh) | 2020-12-29 | 2022-11-01 | 美商Ｓｑｚ生物科技公司 | 以經修飾ｐｂｍｃ治療癌症之方法 |
| JP2024503279A (ja) | 2020-12-29 | 2024-01-25 | スクイーズ バイオテクノロジーズ カンパニー | Ｐｂｍｃの凍結保存のための製剤 |
| US20220233676A1 (en) * | 2020-12-29 | 2022-07-28 | Sqz Biotechnologies Company | Formulations of activating antigen carriers |
| US20220296691A1 (en) | 2020-12-29 | 2022-09-22 | Sqz Biotechnologies Company | Methods for treating cancer with activating antigen carriers |
| CN115252772A (zh) * | 2021-04-30 | 2022-11-01 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
| WO2023010090A1 (en) | 2021-07-29 | 2023-02-02 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| WO2023087009A1 (en) | 2021-11-11 | 2023-05-19 | Sqz Biotechnologies Company | Methods to generate enhanced tumor infiltrating lymphocytes through microfluidic delivery |
| CA3262748A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | IMPROVED ANTIGEN-PRESENTING CELL FORMULATIONS |
| CA3262756A1 (en) | 2022-07-28 | 2024-02-01 | Stemcell Technologies Canada Inc. | CANCER TREATMENT METHODS WITH ENHANCED ANTIGEN-PRESENTING CELLS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007528838A (ja) * | 2003-12-24 | 2007-10-18 | ライデン ユニバーシティ メディカル センター | 腫瘍特異的ワクチンとしての合成タンパク質 |
| ES2482192T3 (es) * | 2007-05-31 | 2014-08-01 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Vacunación intradérmica del péptido de HPV |
| WO2009039125A1 (en) * | 2007-09-17 | 2009-03-26 | The Schepens Eye Research Institute, Inc. | Use of ocular neuropeptides as immune adjuvants |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| CN107058101B (zh) * | 2011-10-17 | 2021-06-01 | 麻省理工学院 | 细胞内传递 |
| US20170212116A1 (en) * | 2014-01-31 | 2017-07-27 | Ulisse Biomed Srl | Biosensors for the detection of infection and associated maladies |
| JP7523203B2 (ja) * | 2014-10-31 | 2024-07-26 | マサチューセッツ インスティテュート オブ テクノロジー | 生体分子の免疫細胞への送達 |
| ES2930017T3 (es) | 2015-09-04 | 2022-12-05 | Sqz Biotechnologies Co | Suministro intracelular de biomoléculas mediado por una superficie con poros |
| CN108779475A (zh) * | 2016-01-12 | 2018-11-09 | Sqz生物技术公司 | 复合物的细胞内递送 |
| US12599656B2 (en) * | 2018-03-12 | 2026-04-14 | Stemcell Technologies Canada Inc. | Methods for treating HPV-associated diseases |
-
2019
- 2019-03-11 EP EP19716612.7A patent/EP3765068A2/en active Pending
- 2019-03-11 CR CR20200460A patent/CR20200460A/es unknown
- 2019-03-11 WO PCT/US2019/021705 patent/WO2019178006A2/en not_active Ceased
- 2019-03-11 CN CN201980030600.3A patent/CN112135627A/zh active Pending
- 2019-03-11 AU AU2019234550A patent/AU2019234550B2/en active Active
- 2019-03-11 CA CA3093828A patent/CA3093828A1/en active Pending
- 2019-03-11 BR BR112020018612-0A patent/BR112020018612A2/pt unknown
- 2019-03-11 US US16/980,339 patent/US20240374654A2/en active Pending
- 2019-03-11 MA MA052010A patent/MA52010A/fr unknown
- 2019-03-11 SG SG11202008864VA patent/SG11202008864VA/en unknown
- 2019-03-11 JP JP2020548778A patent/JP7595827B2/ja active Active
- 2019-03-11 MX MX2020009439A patent/MX2020009439A/es unknown
- 2019-03-11 TW TW108108098A patent/TW202003019A/zh unknown
- 2019-03-11 IL IL277188A patent/IL277188B2/en unknown
- 2019-03-11 KR KR1020207028580A patent/KR20200130835A/ko not_active Ceased
-
2020
- 2020-09-11 PH PH12020551436A patent/PH12020551436A1/en unknown
- 2020-11-03 CO CONC2020/0012584A patent/CO2020012584A2/es unknown
-
2024
- 2024-10-25 JP JP2024188260A patent/JP2025020210A/ja active Pending
-
2026
- 2026-03-03 AU AU2026201618A patent/AU2026201618A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517813A5 (https=) | ||
| JP2021517895A5 (https=) | ||
| IL277188B1 (en) | Intracellular delivery of biomolecules to modify the immune response | |
| Quayle et al. | CUE-101, a novel E7-pHLA-IL2-Fc fusion protein, enhances tumor antigen-specific T-cell activation for the treatment of HPV16-driven malignancies | |
| JPWO2019178006A5 (https=) | ||
| JPWO2019178005A5 (https=) | ||
| von Bergwelt-Baildon et al. | Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application | |
| Shibagaki et al. | Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity | |
| US11377481B2 (en) | SpyCatcher and SpyTag: universal immune receptors for T cells | |
| EP0914416B1 (en) | Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors | |
| CN103898051B (zh) | 提高免疫反应性的方法 | |
| Harmala et al. | The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo | |
| Grodeland et al. | DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza | |
| CN104411819A (zh) | 用于过继细胞疗法的改进的细胞培养方法 | |
| Batista-Duharte et al. | Immune checkpoint inhibitors for vaccine improvements: current status and new approaches | |
| CN104619723A (zh) | 评估用于施用的转导t细胞的适用性的方法 | |
| KR20170074235A (ko) | 면역 세포로의 생체분자의 전달 | |
| KR20170045205A (ko) | 감마 델타 t 세포 및 이의 용도 | |
| TW201247700A (en) | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists | |
| US12473342B2 (en) | Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis | |
| Kan-Mitchell et al. | The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope | |
| JP2021515588A5 (https=) | ||
| Gerloni et al. | T cell immunity using transgenic B lymphocytes | |
| JP2022514116A (ja) | 新規な癌抗原及び方法 | |
| JP2021527419A (ja) | 免疫細胞操作用の安定化されたｍｈｃ分子を有するスカフォールド |